HomeCompareGNRRF vs EPRT

GNRRF vs EPRT: Dividend Comparison 2026

GNRRF yields 43.96% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNRRF wins by $223.6K in total portfolio value
10 years
GNRRF
GNRRF
● Live price
43.96%
Share price
$4.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$287.0K
Annual income
$52,411.25
Full GNRRF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — GNRRF vs EPRT

📍 GNRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNRRFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNRRF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNRRF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNRRF
Annual income on $10K today (after 15% tax)
$3,736.26/yr
After 10yr DRIP, annual income (after tax)
$44,549.56/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, GNRRF beats the other by $33,634.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNRRF + EPRT for your $10,000?

GNRRF: 50%EPRT: 50%
100% EPRT50/50100% GNRRF
Portfolio after 10yr
$175.2K
Annual income
$32,625.99/yr
Blended yield
18.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

GNRRF
No analyst data
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNRRF buys
0
EPRT buys
0
No recent congressional trades found for GNRRF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNRRFEPRT
Forward yield43.96%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$287.0K$63.4K
Annual income after 10y$52,411.25$12,840.73
Total dividends collected$221.7K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: GNRRF vs EPRT ($10,000, DRIP)

YearGNRRF PortfolioGNRRF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$15,096$4,395.60$11,205$505.18+$3.9KGNRRF
2$22,354$6,201.34$12,672$682.46+$9.7KGNRRF
3$32,501$8,582.21$14,490$930.48+$18.0KGNRRF
4$46,437$11,661.61$16,786$1,282.69+$29.7KGNRRF
5$65,260$15,572.20$19,753$1,791.56+$45.5KGNRRF
6$90,281$20,452.54$23,677$2,541.64+$66.6KGNRRF
7$123,043$26,443.04$29,008$3,672.99+$94.0KGNRRF
8$165,338$33,681.45$36,463$5,425.08+$128.9KGNRRF
9$219,210$42,298.12$47,238$8,221.57+$172.0KGNRRF
10$286,966$52,411.25$63,385$12,840.73+$223.6KGNRRF

GNRRF vs EPRT: Complete Analysis 2026

GNRRFStock

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

Full GNRRF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this GNRRF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNRRF vs SCHDGNRRF vs JEPIGNRRF vs OGNRRF vs KOGNRRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.